Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More
DISHMAN PHARMA | STERLING BIOTECH | DISHMAN PHARMA/ STERLING BIOTECH |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 25.1 | -0.4 | - | View Chart |
P/BV | x | 3.3 | 0.0 | 23,491.4% | View Chart |
Dividend Yield | % | 0.7 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DISHMAN PHARMA Mar-16 |
STERLING BIOTECH Dec-13 |
DISHMAN PHARMA/ STERLING BIOTECH |
5-Yr Chart Click to enlarge
|
||
High | Rs | 374 | 11 | 3,565.7% | |
Low | Rs | 129 | 3 | 3,791.2% | |
Sales per share (Unadj.) | Rs | 197.8 | 26.8 | 737.9% | |
Earnings per share (Unadj.) | Rs | 21.2 | -15.0 | -141.8% | |
Cash flow per share (Unadj.) | Rs | 34.7 | -5.5 | -635.6% | |
Dividends per share (Unadj.) | Rs | 2.00 | 0 | - | |
Dividend yield (eoy) | % | 0.8 | 0 | - | |
Book value per share (Unadj.) | Rs | 179.9 | 54.9 | 327.8% | |
Shares outstanding (eoy) | m | 80.69 | 267.87 | 30.1% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 1.3 | 0.3 | 490.7% | |
Avg P/E ratio | x | 11.9 | -0.5 | -2,553.9% | |
P/CF ratio (eoy) | x | 7.2 | -1.3 | -569.7% | |
Price / Book Value ratio | x | 1.4 | 0.1 | 1,104.7% | |
Dividend payout | % | 9.4 | 0 | - | |
Avg Mkt Cap | Rs m | 20,306 | 1,862 | 1,090.7% | |
No. of employees | `000 | 0.8 | 1.4 | 61.2% | |
Total wages/salary | Rs m | 5,355 | 547 | 979.3% | |
Avg. sales/employee | Rs Th | 19,252.7 | 5,303.3 | 363.0% | |
Avg. wages/employee | Rs Th | 6,459.5 | 403.8 | 1,599.5% | |
Avg. net profit/employee | Rs Th | 2,064.1 | -2,959.0 | -69.8% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 15,961 | 7,181 | 222.3% | |
Other income | Rs m | 265 | 43 | 623.0% | |
Total revenues | Rs m | 16,226 | 7,223 | 224.6% | |
Gross profit | Rs m | 4,103 | 947 | 433.3% | |
Depreciation | Rs m | 1,091 | 2,543 | 42.9% | |
Interest | Rs m | 944 | 4,377 | 21.6% | |
Profit before tax | Rs m | 2,334 | -5,931 | -39.3% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 1 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 624 | -1,924 | -32.4% | |
Profit after tax | Rs m | 1,711 | -4,007 | -42.7% | |
Gross profit margin | % | 25.7 | 13.2 | 195.0% | |
Effective tax rate | % | 26.7 | 32.4 | 82.4% | |
Net profit margin | % | 10.7 | -55.8 | -19.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,018 | 14,335 | 76.9% | |
Current liabilities | Rs m | 9,517 | 49,809 | 19.1% | |
Net working cap to sales | % | 9.4 | -494.0 | -1.9% | |
Current ratio | x | 1.2 | 0.3 | 402.3% | |
Inventory Days | Days | 110 | 403 | 27.4% | |
Debtors Days | Days | 35 | 171 | 20.4% | |
Net fixed assets | Rs m | 16,304 | 55,432 | 29.4% | |
Share capital | Rs m | 161 | 268 | 60.2% | |
"Free" reserves | Rs m | 12,907 | 13,935 | 92.6% | |
Net worth | Rs m | 14,516 | 14,701 | 98.7% | |
Long term debt | Rs m | 4,189 | 9,478 | 44.2% | |
Total assets | Rs m | 29,805 | 73,988 | 40.3% | |
Interest coverage | x | 3.5 | -0.4 | -977.9% | |
Debt to equity ratio | x | 0.3 | 0.6 | 44.8% | |
Sales to assets ratio | x | 0.5 | 0.1 | 551.8% | |
Return on assets | % | 8.9 | 0.5 | 1,778.7% | |
Return on equity | % | 11.8 | -27.3 | -43.3% | |
Return on capital | % | 17.5 | -6.4 | -272.8% | |
Exports to sales | % | 24.8 | 25.9 | 95.7% | |
Imports to sales | % | 3.7 | 0.2 | 2,199.0% | |
Exports (fob) | Rs m | 3,956 | 1,860 | 212.7% | |
Imports (cif) | Rs m | 596 | 12 | 4,887.7% | |
Fx inflow | Rs m | 4,952 | 1,860 | 266.2% | |
Fx outflow | Rs m | 697 | 25 | 2,799.5% | |
Net fx | Rs m | 4,255 | 1,835 | 231.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,786 | 1,719 | 162.1% | |
From Investments | Rs m | -1,529 | -3,148 | 48.6% | |
From Financial Activity | Rs m | -941 | 1,426 | -66.0% | |
Net Cashflow | Rs m | 316 | -3 | -9,305.9% |
Indian Promoters | % | 61.4 | 33.9 | 181.1% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 3.7 | 0.0 | - | |
FIIs | % | 12.7 | 9.9 | 128.3% | |
ADR/GDR | % | 0.0 | 16.9 | - | |
Free float | % | 22.1 | 39.3 | 56.2% | |
Shareholders | 46,261 | 21,482 | 215.3% | ||
Pledged promoter(s) holding | % | 35.8 | 55.9 | 63.9% |
Compare DISHMAN PHARMA With: SANOFI INDIA ABBOTT INDIA FRESENIUS KABI ONCO. WYETH TORRENT PHARMA
Compare DISHMAN PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Asian share markets rose for the third straight session today, tracking gains in US peers. The Nikkei is trading up by 0.7% and the Hang Seng is trading up by 0.1%.
The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Our ace stock picker is ready to capitalise on a big growth opportunity.
More